Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

996 questions · 1,049 findings · 79 reviews · Dementia and Cognitive Improvement

No studies found 240 · 22.9%GRADE not reported 31 · 3%Very low 216 · 20.6%Low 253 · 24.1%Moderate 238 · 22.7%High 71 · 6.8%

Intervention not reported

Falls ‐ not measured · adults with cognitive impairment/dementia and cognitively intact populations

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Hospitalisations (at 4 months' · adults with cognitive impairment/dementia and cognitively intact populations

The intervention showed no clear difference in hospitalisations (at 4 months' (low certainty).

1 finding from 1 review

Rivastigmine vs placebo

Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Rivastigmine vs placebo

Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to lower physician rated global impression tests (no change or worse compared… compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Behavioural symptoms (change from baseline at 26 weeks measured using various scales) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Rivastigmine vs placebo

Acceptability · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease

Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Rivastigmine vs placebo

Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Intervention not reported

Cognition, SD units Investigators measured cognition using different instruments. Higher scores represent better cognitive function · people with dementia
1 finding from 1 review

Intervention not reported

Activities of daily living, SD units Investigators measured ADLs using different instruments. Higher scores represent better performance · people with dementia
1 finding from 1 review

Intervention not reported

Depression, SD units Investigators measured depression using a variety of scales. Lower scores represent improvement · people with dementia
1 finding from 1 review

Intervention not reported

Neuropsychiatric symptoms Measured using NPI. Severity of symptoms is measured on a scale of 0‐144. A higher score indicates worse symptoms · people with dementia
1 finding from 1 review

Case management vs usual care

Institutionalised (number of participants admitted to residential or nursing homes) at 10 ‐ 12 months · people with dementia

Case management showed no clear difference in institutionalised (number of participants admitted to residential or… compared with usual care (low certainty).

1 finding from 1 review